Vaxcyte, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Vaxcyte, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Market Positioning Management attributes the VAX-31 opportunity to persistent gaps in serotype coverage despite decades of vaccination, positioning their 31-valent candidate to protect against both historical and currently circulating strains. The adult PCV market is experiencing accelerating growth driven by expanded U.S. age recommendations (50+) and increasing international adoption, reinforcing the demand for broader spectrum protection. Operational focus has shifted toward establishing a 'totality of data' framework for VAX-31, where the goal is to demonstrate superior public health impact rather than perfection on every individual serotype comparison. The company completed construction of a dedicated large-scale manufacturing facility on time and budget, a critical step in transitioning from a clinical-stage entity to a global commercial enterprise. Strategic organizational scaling is underwa
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]Yahoo! Finance
- Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists [Yahoo! Finance]Yahoo! Finance
- A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (PCVX) had its "buy" rating reaffirmed by BTIG Research.MarketBeat
PCVX
Earnings
- 2/24/26 - Miss
PCVX
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- PCVX's page on the SEC website